MX2020004897A - Acidos nucleicos para inhibir la expresion de lpa en una celula. - Google Patents

Acidos nucleicos para inhibir la expresion de lpa en una celula.

Info

Publication number
MX2020004897A
MX2020004897A MX2020004897A MX2020004897A MX2020004897A MX 2020004897 A MX2020004897 A MX 2020004897A MX 2020004897 A MX2020004897 A MX 2020004897A MX 2020004897 A MX2020004897 A MX 2020004897A MX 2020004897 A MX2020004897 A MX 2020004897A
Authority
MX
Mexico
Prior art keywords
expression
inhibit
lpa
cell
nucleic acids
Prior art date
Application number
MX2020004897A
Other languages
English (en)
Inventor
Lucas Bethge
Judith Hauptmann
Christian Frauendorf
Adrien Weingärtner
Sibylle Dames
Steffen Schubert
Stephan Tenbaum
David Anthony Rider
Original Assignee
Silence Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17201449.0A external-priority patent/EP3483270A1/en
Application filed by Silence Therapeutics Gmbh filed Critical Silence Therapeutics Gmbh
Publication of MX2020004897A publication Critical patent/MX2020004897A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a productos y composiciones y sus usos. En particular, la invencion se relaciona a productos de ácido nucleico que interfieren con la expresion del gen LPA o inhiben su expresion para uso como tratamiento, prevención o reduccion del riesgo de sufrir enfermedad cardiovascular tal como cardiopatía coronaria o estenosis de la aorta o accidente cardiovascular o cualquier otro trastorno, patología o síndrome relacionado con niveles elevados de partículas que contienen Lp(a).
MX2020004897A 2017-11-13 2018-11-13 Acidos nucleicos para inhibir la expresion de lpa en una celula. MX2020004897A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17201449.0A EP3483270A1 (en) 2017-11-13 2017-11-13 Products and compositions
EP18179175.7A EP3483271A3 (en) 2017-11-13 2018-06-21 Products and compositions
GB201815915 2018-09-28
PCT/EP2018/081106 WO2019092283A1 (en) 2017-11-13 2018-11-13 Nucleic acids for inhibiting expression of lpa in a cell

Publications (1)

Publication Number Publication Date
MX2020004897A true MX2020004897A (es) 2020-10-05

Family

ID=66439085

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004897A MX2020004897A (es) 2017-11-13 2018-11-13 Acidos nucleicos para inhibir la expresion de lpa en una celula.

Country Status (22)

Country Link
US (3) US11319537B2 (es)
EP (2) EP3710586B1 (es)
JP (1) JP7245254B2 (es)
KR (1) KR102553382B1 (es)
CN (2) CN111465694A (es)
AU (1) AU2018363840B2 (es)
BR (1) BR112020009152A2 (es)
CA (1) CA3081905C (es)
DK (1) DK3710586T3 (es)
ES (1) ES2938193T3 (es)
FI (1) FI3710586T3 (es)
HR (1) HRP20230127T1 (es)
HU (1) HUE061265T2 (es)
IL (1) IL274503B2 (es)
LT (1) LT3710586T (es)
MX (1) MX2020004897A (es)
PL (1) PL3710586T3 (es)
RS (1) RS63955B1 (es)
SG (1) SG11202003230UA (es)
SI (1) SI3710586T1 (es)
WO (1) WO2019092283A1 (es)
ZA (1) ZA202003371B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE065423T2 (hu) 2015-12-16 2024-05-28 6K Inc Eljárás szferoidális dehidrogénezett titánötvözet részecskék elõállítására
US10987735B2 (en) 2015-12-16 2021-04-27 6K Inc. Spheroidal titanium metallic powders with custom microstructures
JP7155239B2 (ja) * 2017-04-05 2022-10-18 サイレンス・セラピューティクス・ゲーエムベーハー 産物及び組成物
MX2020004897A (es) 2017-11-13 2020-10-05 Silence Therapeutics Gmbh Acidos nucleicos para inhibir la expresion de lpa en una celula.
WO2019143621A1 (en) 2018-01-16 2019-07-25 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting aldh2 expression
AU2019290663B2 (en) 2018-06-19 2023-05-04 6K Inc. Process for producing spheroidized powder from feedstock materials
BR112021009213A2 (pt) * 2018-11-13 2021-08-10 Silence Therapeutics Gmbh ácidos nucleicos para inibição da expressão de lpa em uma célula
CA3135402A1 (en) * 2019-04-04 2020-10-08 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression in the central nervous system
CA3134573A1 (en) 2019-04-30 2020-11-05 Sunil Bhalchandra BADWE Mechanically alloyed powder feedstock
WO2021118762A1 (en) 2019-11-18 2021-06-17 6K Inc. Unique feedstocks for spherical powders and methods of manufacturing
US20230078200A1 (en) * 2019-12-09 2023-03-16 Amgen Inc. RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
AU2021297476A1 (en) 2020-06-25 2022-12-15 6K Inc. Microcomposite alloy structure
KR102812602B1 (ko) 2020-08-05 2025-05-28 다이서나 파마수이티컬, 인크. Lpa 발현을 저해하기 위한 조성물 및 방법
AU2021349358A1 (en) 2020-09-24 2023-02-09 6K Inc. Systems, devices, and methods for starting plasma
US20240035029A1 (en) * 2020-10-16 2024-02-01 Sanofi Rna compositions and methods for inhibiting lipoprotein(a)
EP4237174A1 (en) 2020-10-30 2023-09-06 6K Inc. Systems and methods for synthesis of spheroidized metal powders
WO2022098841A1 (en) * 2020-11-05 2022-05-12 Amgen Inc. METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS
US20250304966A1 (en) 2020-12-23 2025-10-02 Argonaute RNA Limited Treatment of cardiovascular disease
EP4275239A4 (en) 2021-01-11 2024-12-18 6K Inc. METHODS AND SYSTEMS FOR RECLAIMING LI-ION CATHODE MATERIALS USING MICROWAVE PLASMA TREATMENT
AU2022246797A1 (en) 2021-03-31 2023-10-05 6K Inc. Systems and methods for additive manufacturing of metal nitride ceramics
WO2023041508A2 (en) 2021-09-14 2023-03-23 Argonaute RNA Limited Treatment of cardiovascular disease
IL312811A (en) 2021-11-16 2024-07-01 Shanghai Argo Biopharmaceutical Co Ltd Composition and method for inhibiting angiotensinogen (agt) protein expression
IL312743A (en) * 2021-11-18 2024-07-01 Novartis Ag Compounds targeting PMP22 for the treatment of Charcot-Marie-Shen disease
PE20241340A1 (es) 2021-11-24 2024-07-03 Adarx Pharmaceuticals Inc Composiciones moduladoras de complemento del factor b y metodos de uso de estas
TW202345865A (zh) * 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
CN114703184B (zh) * 2022-03-11 2024-06-18 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
EP4522742A2 (en) 2022-05-13 2025-03-19 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2023229928A1 (en) 2022-05-23 2023-11-30 6K Inc. Microwave plasma apparatus and methods for processing materials using an interior liner
US12040162B2 (en) 2022-06-09 2024-07-16 6K Inc. Plasma apparatus and methods for processing feed material utilizing an upstream swirl module and composite gas flows
WO2024006999A2 (en) 2022-06-30 2024-01-04 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
WO2024044498A1 (en) 2022-08-25 2024-02-29 6K Inc. Plasma apparatus and methods for processing feed material utilizing a powder ingress preventor (pip)
CN115851723B (zh) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用
US12195338B2 (en) 2022-12-15 2025-01-14 6K Inc. Systems, methods, and device for pyrolysis of methane in a microwave plasma for hydrogen and structured carbon powder production
IL321855A (en) * 2023-01-13 2025-08-01 Lilly Co Eli Pharmaceutical preparations containing therapeutic oligonucleotides and dosage regimens using the same
WO2024238385A2 (en) 2023-05-12 2024-11-21 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2024240056A1 (zh) 2023-05-19 2024-11-28 深圳信立泰药业股份有限公司 一种磺酰胺类化合物及其制备方法和医药用途
CN119563025A (zh) 2023-07-04 2025-03-04 石药集团中奇制药技术（石家庄）有限公司 一种抑制LP(a)基因表达的dsRNA分子及其应用
WO2025082058A1 (zh) * 2023-10-16 2025-04-24 润佳(上海)医药技术有限公司 一种抑制LPA基因表达的dsRNA及其用途
WO2025103391A1 (zh) * 2023-11-15 2025-05-22 北京加科瑞康医药科技有限公司 用于抑制lpa的基因表达的sirna，含其的组合物及其用途
CN120098993A (zh) * 2023-12-05 2025-06-06 广东东阳光药业股份有限公司 一种新型的双链siRNA、其缀合物及其用途
WO2026008063A1 (en) * 2024-07-05 2026-01-08 Geneditbio Limited Methods and compositions for lpa gene editing and therapy using crispr system
WO2026046152A1 (zh) * 2024-08-26 2026-03-05 倍臻生物技术（苏州）有限公司 修饰的双链核糖核酸及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
US20060160759A1 (en) * 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
US20110110886A1 (en) * 2008-06-13 2011-05-12 Yale University Small molecule inhibitors of autotaxin and methods of use
CN108148838A (zh) * 2012-05-22 2018-06-12 奥利克斯医药有限公司 具有细胞内穿透能力的诱导rna干扰的核酸分子及用途
US20160272970A1 (en) * 2015-03-17 2016-09-22 Arrowhead Madison Inc. RNA Interference Agents
JOP20160211B1 (ar) * 2015-10-01 2021-08-17 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
EP3228326A1 (en) * 2016-04-05 2017-10-11 Silence Therapeutics GmbH Nucleic acid linked to a trivalent glycoconjugate
JP7155239B2 (ja) 2017-04-05 2022-10-18 サイレンス・セラピューティクス・ゲーエムベーハー 産物及び組成物
CA3118327A1 (en) 2017-11-13 2019-05-16 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of aldh2 in a cell
MX2020004897A (es) 2017-11-13 2020-10-05 Silence Therapeutics Gmbh Acidos nucleicos para inhibir la expresion de lpa en una celula.
BR112021009213A2 (pt) 2018-11-13 2021-08-10 Silence Therapeutics Gmbh ácidos nucleicos para inibição da expressão de lpa em uma célula

Also Published As

Publication number Publication date
US20220290144A1 (en) 2022-09-15
US11319537B2 (en) 2022-05-03
EP4219716A2 (en) 2023-08-02
US12054717B2 (en) 2024-08-06
IL274503A (en) 2020-06-30
CN111465694A (zh) 2020-07-28
KR20200088392A (ko) 2020-07-22
AU2018363840B2 (en) 2022-09-29
US20240327843A1 (en) 2024-10-03
IL274503B2 (en) 2024-10-01
EP3710586B1 (en) 2022-11-23
EP3710586A1 (en) 2020-09-23
HUE061265T2 (hu) 2023-06-28
US20210123048A1 (en) 2021-04-29
KR102553382B1 (ko) 2023-07-07
RS63955B1 (sr) 2023-02-28
SG11202003230UA (en) 2020-05-28
AU2018363840A1 (en) 2020-04-16
PL3710586T3 (pl) 2023-03-20
FI3710586T3 (fi) 2023-03-02
BR112020009152A2 (pt) 2020-10-27
HRP20230127T1 (hr) 2023-03-31
DK3710586T3 (da) 2023-01-23
CA3081905C (en) 2023-10-03
WO2019092283A1 (en) 2019-05-16
CA3081905A1 (en) 2019-05-16
ES2938193T3 (es) 2023-04-05
CN119120476A (zh) 2024-12-13
LT3710586T (lt) 2023-02-27
JP7245254B2 (ja) 2023-03-23
IL274503B1 (en) 2024-06-01
SI3710586T1 (sl) 2023-03-31
JP2021502120A (ja) 2021-01-28
EP4219716A3 (en) 2024-03-27
ZA202003371B (en) 2023-08-30

Similar Documents

Publication Publication Date Title
MX2020004897A (es) Acidos nucleicos para inhibir la expresion de lpa en una celula.
CL2021001225A1 (es) Ácidos nucleicos para inhibir la expresión de lpa en una célula
CO2017004728A2 (es) Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa)
PE20201287A1 (es) Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
PE20181139A1 (es) Composiciones y metodos para inhibir la expresion genica de lpa
BR112016029041A2 (pt) terapia de combinação com inibidores de glutaminase
MX393975B (es) Plantas que muestran una reducción en el cambio de coloración en la superficie inducido por heridas.
MX2016010071A (es) Composiciones farmaceuticas que comprenden un farmaco antipsicotico y un inhibidor de la isoforma 2 del transportador de monomina vesicular (vmat2) y sus usos.
MX2017016289A (es) Mutaciones de la enzima crispr que reducen los efectos fuera del blanco.
MX2020004898A (es) Ácidos nucleicos para inhibir la expresión de un gen diana que comprende enlaces fosforoditioato.
MX389847B (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
MX379262B (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
MX2017011500A (es) Combinaciones y formulaciones de dosis fijas que comprenden ácido 8-hidroxi-2,2,14,14- tetrametilpentadecanodioico (etc1002) y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MX387275B (es) Neoepítopos virales y sus usos
PH12017501692A1 (en) Solid forms of menaquinols
EP3483271A3 (en) Products and compositions
UY37294A (es) Promotor vegetal y 3# utr para la expresión de transgenes
MX377962B (es) Composición líquida tópica que comprende melatonina.
AR122920A1 (es) Actividad anticancerígena de las sales de perborato
Mendiola Mejía The Historical Explanation: The Part Played by Narratives. Notes on narration and knowledge in Arthur C. Danto
Galtseva CHARACTER OF" NEW" RUSSIAN LANGUAGE. DEMOCRATIZATION, ADAPTATION OR DEGRADATION?(WHAT ARE THE SOURCES OF REPLENISHMENT OF LEXICAL STRUCTURE OF RUSSIAN LANGUAGE TODAY)
AR103676A1 (es) COMPOSICIONES DE ARNi QUE CONTIENEN UN DOMINIO FOSFOLIPASA TIPO PATATINA 3 (PNPLA3) Y SUS MÉTODOS DE USO
Yan et al. A Study of Amplification in Consecutive Interpreting
Álvarez The Figures of the Just and the Unjust Men in Republic II as Precedents of the Philosopher and the Sophist in Plato's Sophist